Publication Author: Basu_Anirban

• Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.

  Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. J Manag Care Spec Pharm. 2017 Oct;23(10):108

  rakerr2

  October 1, 2017

• Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.

  Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, Sen SS, Basu A. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United State

  rakerr2

  April 28, 2017

• Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.

  Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF. Economic analysis of the Phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017 Mar 2. doi: 10.1080/14737

  rakerr2

  April 1, 2017

• Mothers’ Employment Attributes and Use of Preventive Child Health Services.

  Shepherd-Banigan M, Bell JF, Basu A, Booth-LaForce C, Harris JR. Mothers’ Employment Attributes and Use of Preventive Child Health Services. Med Care Res Rev. 2017 Apr;74(2):208-226. doi: 10.1177/1077558716634555. Epub 2016 Aug 3.

  rakerr2

  April 1, 2017

• 2SLS vs 2SRI: Appropriate Methods for Rare Outcomes and/or Rare Exposures.

  Basu A, Coe NB. 2SLS vs 2SRI: Appropriate Methods for Rare Outcomes and/or Rare Exposures. Health Econ. 2017 Mar 5. doi: 10.1002/hec.3490. [Epub ahead of print]

  rakerr2

  March 5, 2017

• Impact of a value-based formulary in three chronic disease cohorts.

  Yeung K, Basu A, Marcum ZA, Watkins JB, Sullivan SD. Impact of a value-based formulary in three chronic disease cohorts. Am J Manag Care. 2017 Mar;23(3 Suppl):S46-S53. doi: 87035.

  rakerr2

  March 1, 2017

• Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.

  Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Med Care. 2017 Feb;55(2):191-198. doi: 10.1097/MLR.0000000000000630.

  rakerr2

  February 1, 2017

• Toward a Hedonic Value Framework in Health Care.

  Basu A, Sullivan SD. Toward a Hedonic Value Framework in Health Care. Value Health. 2017 Feb;20(2):261-265. doi: 10.1016/j.jval.2016.11.022.

  rakerr2

  February 1, 2017

• Measuring the Value of Pharmaceuticals in the US Health System.

  Walton SM, Basu A, Mullahy J, Hong S, Schumock GT. Measuring the Value of Pharmaceuticals in the US Health System. Pharmacoeconomics. 2017 Jan;35(1):1-4. doi: 10.1007/s40273-016-0463-3.

  rakerr2

  January 1, 2017

• Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.

  Wang WJ, Robertson JC, Basu A. Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers. J Comp Eff Res. 2017 Jan;6(1):15-24. doi: 10.2217/cer-2016-0021.

  rakerr2

  January 1, 2017